

ASX Announcement

Date of AGM and Closing Date for Director Nominations

5 October 2021 – Race Oncology Limited (“Race”) advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held on Tuesday, 23 November 2021. The Company will follow the measures in place as set by the Australian and New South Wales governments for the restriction of gatherings and the implementation of social distancing requirements in respect of COVID-19.

An item of business at the AGM will be the re-election and appointment of Directors. In accordance with clause 14.3 of the Company’s Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a Director is Tuesday, 12 October 2021.

Any nominations must be received by the Company in writing by no later than 5.00 pm (Sydney time) on Tuesday, 12 October 2021.

-ENDS

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene® (bisantrene dihydrochloride).

Zantrene® is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene® as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Zantrene® as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development and regulatory approval of Zantrene®.

See more at www.raceoncology.com.

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au